^
    Back
    Association details:
    Biomarker:EZH2 overexpression
    Cancer:Adrenal Cortex Carcinoma
    Drug Class:EZH2 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Hum Mol Genet
    Title:

    EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression

    Excerpt:
    EZH2 overexpression is associated with ACC cell growth...EZH2 inhibition inhibits aggressive behaviour and induces apoptosis of H295R cells...the combination of 10 µM mitotane and 5 µM DZNep induced a more significant growth rate reduction than 10 µM mitotane alone...
    Secondary therapy:
    mitotane
    DOI:
    10.1093/hmg/ddw136